Velos, Inc. Unveils Free iPad Apps for Oncology Adverse Event Management and Graft-versus-host Disease Tracking

FREMONT, Calif., Feb. 1, 2012 /PRNewswire/ -- Velos, Inc., a healthcare technology company, will unveil its Velos Aversi and Velos Aversi GVHD iPad apps at the 2012 Bone Marrow Transplant (BMT) Tandem Meetings in San Diego, California, February 1-4, 2012. Velos Aversi is designed to enhance point-of-care recording and tracking of adverse events based on the Common Terminology Criteria for Adverse Events (CTCAE). Velos Aversi GVHD enables clinicians to assess, track, and review graft-versus-host disease (GVHD) status along with clinical trial adverse events.

"It's exciting to release our products to the Bone Marrow Transplant community at this meeting," said John McIlwain, CEO and President of Velos. "We think Velos Aversi GVHD's precise graft-versus-host Disease (GVHD) tracking make it an invaluable tool for bone marrow transplant procedures. Just as exciting is Velos Aversi's global applicability in all clinical trials in oncology," Mr. McIlwain added.

Dr. Roy Jones, MD, PhD, from the Cellular Transplantation and Cellular Therapy Department at the MD Anderson Cancer Center in Houston, Texas, will introduce Velos Aversi at the BMT Meetings. Dr. David Miklos, MD, PhD, from the Blood and Marrow Transplant Center at Stanford University will discuss his thoughts on design and applicability of the Velos Aversi GVHD app on Friday, February 3 at 7:00AM (PST) in the Manchester ABC Ballroom at the Manchester Grand Hyatt Hotel in San Diego.

Currently, clinicians rely on static, unconnected charts and manual systems to evaluate patients with toxicities, as well as unexpected events during clinical trials or after bone marrow transplant procedures. As a result, clinicians must record multiple events continuously without the bedside tools to review previous records in a visually friendly format. Furthermore, the multi-system nature of GVHD makes classification of the disease highly complex, often resulting in the delay of important procedures, patient reviews, and decisions, which can lead to compromises in compliance, timelines, and needs.

Aversi remedies these problems with its unified data collection and dynamic information tracking. The app enables the physician to manage data more efficiently and review adverse event history, resulting in improved patient care. This app is just one of many enabling products – Velos now offers a full suite that tracks labs, adverse events, and appropriate rules and workflows with Velos eResearch and Velos Comaiba.

"Streamlining GVHD and adverse events management at the point-of-care is a part of Velos' pioneering work in mobile clinical and research applications as we continue to empower clinicians through innovation," said Cody Kang, PhD, who leads development in cellular therapy for Velos' products. "We look forward to releasing more applications throughout this year."

Velos Aversi and Velos Aversi GVHD will soon be available free for individual download. Interested clinicians are invited to learn how to access these downloads at the talk on Friday, visit the Velos booth at the BMT Tandem meeting in San Diego, or read about it on the web at www.velos.com.

About Velos – Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S.  Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. System users are freed of redundant data entry and related time delays associated with most clinical research today. Velos integrates the clinical, administrative and financial information needs of research management, with an emphasis on flexibility and work-flow. Founded in 1996, Velos, Inc. is privately held with headquarters in Fremont, California.  For more information, visit http://www.velos.com/

*This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

SOURCE Velos, Inc.